Jun Arima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Arima has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Kohei Taniguchi
Center for Medical Research and Development, Division of Translational Research, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
3 shared publications- Atsushi Tomioka
Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
2 shared publications Kazuhisa Uchiyama
Osaka Medical College
2 shared publications- Kensuke Nakanishi
Department of Pathology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City 569-8686, Osaka, Japan
2 shared publications - Kenta Hosomi
Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki City 569-1094, Osaka, Japan
2 shared publications - Ko Fujimori
Department of Pathobiochemistry, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 585
Presence of Tuft Cells Expressing Hematopoietic Prostaglandin D Synthase in Acinar-to-Ductal Metaplasia in Human Obstructive Pancreatitis
Acinar-to-ductal metaplasia (ADM)—a process involving the dedifferentiation or transdifferentiation of pancreatic acinar cells—is recognized as an initial event in pancreatic tumorigenesis. Studies in mouse models have revealed that tuft cells, which are chemosensory epithelial cells, appear in ADM following tissue injury, and tuft cell-produced prostaglandin (PG) D2 may suppress inflammation and tumorigenesis. However, the presence and role of tuft cells in the human pancreas remain unclear. Therefore, in this study, we investigated the presence of tuft cells and PGD2 production in human ADM. We analyzed ADM lesions from consecutive patients undergoing surgical resection for pancreatic tumors using dual immunohistochemical staining for POU domain class 2 transcription factor 3 (POU2F3) and hematopoietic PGD synthase (H-PGDS). All 29 patients (13 men and 16 women) with diagnoses including pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms exhibited ADM in regions of obstructive pancreatitis. Immunohistochemical analysis showed that 67.3% of ADM lesions contained POU2F3- and/or H-PGDS-positive cells. Among these, 85.5% of POU2F3-positive cells co-expressed H-PGDS, and 76.2% of H-PGDS-positive cells were POU2F3-positive. These findings indicate that tuft cells present in human ADM produce PGD2, suggesting a role in tissue repair. Tuft cells may represent a potential therapeutic target in pancreatitis, warranting further investigation into their functional role in ADM.
- 2 June 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 585
Open AccessPresence of Tuft Cells Expressing Hematopoietic Prostaglandin D Synthase in Acinar-to-Ductal Metaplasia in Human Obstructive Pancreatitis
Acinar-to-ductal metaplasia (ADM)—a process involving the dedifferentiation or transdifferentiation of pancreatic acinar cells—is recognized as an initial event in pancreatic tumorigenesis. Studies in mouse models have revealed that tuft cells, which are chemosensory epithelial cells, appear in ADM following tissue injury, and tuft cell-produced prostaglandin (PG) D2 may suppress inflammation and tumorigenesis. However, the presence and role of tuft cells in the human pancreas remain unclear. Therefore, in this study, we investigated the presence of tuft cells and PGD2 production in human ADM. We analyzed ADM lesions from consecutive patients undergoing surgical resection for pancreatic tumors using dual immunohistochemical staining for POU domain class 2 transcription factor 3 (POU2F3) and hematopoietic PGD synthase (H-PGDS). All 29 patients (13 men and 16 women) with diagnoses including pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasms exhibited ADM in regions of obstructive pancreatitis. Immunohistochemical analysis showed that 67.3% of ADM lesions contained POU2F3- and/or H-PGDS-positive cells. Among these, 85.5% of POU2F3-positive cells co-expressed H-PGDS, and 76.2% of H-PGDS-positive cells were POU2F3-positive. These findings indicate that tuft cells present in human ADM produce PGD2, suggesting a role in tissue repair. Tuft cells may represent a potential therapeutic target in pancreatitis, warranting further investigation into their functional role in ADM.
- Open Access
- 8 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1944
Immunohistochemical Demonstration of Tuft Cells in Human Acinar-to-Ductal Metaplasia and Pancreatic Intraepithelial Neoplasia
Background/Objectives: Acinar-to-ductal metaplasia (ADM) refers to the dedifferentiation or transdifferentiation of pancreatic acinar cells. Recently, ADM has received considerable attention as a potential precursor of pancreatic tumours. Previous studies in mouse models identified tuft cells, chemosensory epithelial cells, in ADM and pancreatic intraepithelial neoplasia (PanIN), both considered precursor lesions of pancreatic ductal adenocarcinoma (PDAC), but not in PDAC. We examined the presence of tuft cells in human ADM and PanIN. Methods: We analysed tissue samples from 29 patients (16 women, 13 men; median age 74 years) who underwent surgical resection for pancreatic tumours. Immunohistochemical staining for the tuft cell marker, POU2F3, was used to detect tuft cells in ADM and PanIN lesions. Results: ADM was present in all patients. POU2F3-positive tuft cells were observed in 46.4% of ADM lesions (327/705) but not in normal pancreatic acini. The number of POU2F3-positive tuft cells per PanIN area were significantly higher in low-grade PanIN (median, 2 cells; range, 0–20 positive cells) than in high-grade PanIN (median, 0 cell; range 0–4 positive cells) (p = 0.0050). The percentage of POU2F3-positive tuft cells per total cells in low-grade PanIN lesions (median, 1.1%; range 0–2.5%) was also significantly higher than that in high-grade PanIN lesions (median, 0%; range 0–1.1%) (p = 0.0044). Conclusions: Our results suggest that tuft cells emerge in human pancreatic acini during ADM, possibly as part of tissue repair following injury.
- 8 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1944
Open AccessImmunohistochemical Demonstration of Tuft Cells in Human Acinar-to-Ductal Metaplasia and Pancreatic Intraepithelial Neoplasia
Background/Objectives: Acinar-to-ductal metaplasia (ADM) refers to the dedifferentiation or transdifferentiation of pancreatic acinar cells. Recently, ADM has received considerable attention as a potential precursor of pancreatic tumours. Previous studies in mouse models identified tuft cells, chemosensory epithelial cells, in ADM and pancreatic intraepithelial neoplasia (PanIN), both considered precursor lesions of pancreatic ductal adenocarcinoma (PDAC), but not in PDAC. We examined the presence of tuft cells in human ADM and PanIN. Methods: We analysed tissue samples from 29 patients (16 women, 13 men; median age 74 years) who underwent surgical resection for pancreatic tumours. Immunohistochemical staining for the tuft cell marker, POU2F3, was used to detect tuft cells in ADM and PanIN lesions. Results: ADM was present in all patients. POU2F3-positive tuft cells were observed in 46.4% of ADM lesions (327/705) but not in normal pancreatic acini. The number of POU2F3-positive tuft cells per PanIN area were significantly higher in low-grade PanIN (median, 2 cells; range, 0–20 positive cells) than in high-grade PanIN (median, 0 cell; range 0–4 positive cells) (p = 0.0050). The percentage of POU2F3-positive tuft cells per total cells in low-grade PanIN lesions (median, 1.1%; range 0–2.5%) was also significantly higher than that in high-grade PanIN lesions (median, 0%; range 0–1.1%) (p = 0.0044). Conclusions: Our results suggest that tuft cells emerge in human pancreatic acini during ADM, possibly as part of tissue repair following injury.
- 25 June 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (5) , 924-934
Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumors
Background Boron neutron capture therapy selectively delivers the boron isotope 10B to tumors, where neutron irradiation induces a nuclear reaction that generates particle radiation, eradicating cancer cells. Imatinib and other drug therapies remain standard treatments for recurrent and unresectable gastrointestinal stromal tumors; however, their efficacy is limited by drug resistance. Therefore, developing novel therapeutic strategies for unresectable gastrointestinal stromal tumors is essential. This study aimed to investigate the therapeutic potential of boron neutron capture therapy for recurrent and unresectable gastrointestinal stromal tumors. Methods The GIST-T1 cell line and its imatinib-resistant variant (GIST-T1/IM-R) were utilized to assess boronophenylalanine uptake and evaluate boron neutron capture therapy efficacy in both in vitro and in vivo models. Results Boronophenylalanine was substantially incorporated into GIST-T1 and GIST-T1/IM-R cells. Boron neutron capture therapy significantly reduced survival fractions in both cell lines compared to neutron irradiation alone. In the GIST-T1 mouse model, high boronophenylalanine uptake was observed 3 h post-administration, resulting in significant tumor growth suppression following boron neutron capture therapy. Elevated expression of cleaved PARP, Caspase-3, Caspase-8, and γH2AX significantly increased in GIST-T1 tumors post-boron neutron capture therapy. Conclusions The results indicate that boron neutron capture therapy suppresses tumor growth by inducing extrinsic apoptosis through severe DNA damage. This study suggests that boron neutron capture therapy is a promising alternative treatment for gastrointestinal stromal tumors, particularly for cases exhibiting resistance to conventional therapies. Graphical abstract
- 25 June 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (5) , 924-934
Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumors
Background Boron neutron capture therapy selectively delivers the boron isotope 10B to tumors, where neutron irradiation induces a nuclear reaction that generates particle radiation, eradicating cancer cells. Imatinib and other drug therapies remain standard treatments for recurrent and unresectable gastrointestinal stromal tumors; however, their efficacy is limited by drug resistance. Therefore, developing novel therapeutic strategies for unresectable gastrointestinal stromal tumors is essential. This study aimed to investigate the therapeutic potential of boron neutron capture therapy for recurrent and unresectable gastrointestinal stromal tumors. Methods The GIST-T1 cell line and its imatinib-resistant variant (GIST-T1/IM-R) were utilized to assess boronophenylalanine uptake and evaluate boron neutron capture therapy efficacy in both in vitro and in vivo models. Results Boronophenylalanine was substantially incorporated into GIST-T1 and GIST-T1/IM-R cells. Boron neutron capture therapy significantly reduced survival fractions in both cell lines compared to neutron irradiation alone. In the GIST-T1 mouse model, high boronophenylalanine uptake was observed 3 h post-administration, resulting in significant tumor growth suppression following boron neutron capture therapy. Elevated expression of cleaved PARP, Caspase-3, Caspase-8, and γH2AX significantly increased in GIST-T1 tumors post-boron neutron capture therapy. Conclusions The results indicate that boron neutron capture therapy suppresses tumor growth by inducing extrinsic apoptosis through severe DNA damage. This study suggests that boron neutron capture therapy is a promising alternative treatment for gastrointestinal stromal tumors, particularly for cases exhibiting resistance to conventional therapies. Graphical abstract
- Open Access
- 13 February 2021
- Published by Wiley
Staple line reinforcement to reduce leakage in open surgery for Zenker's diverticulum? A case report and literature review
A linear stapler was used to reduce the leakage rate during a Zenker’s diverticulum diverticulectomy. However, staple line reinforcement was not used, and leakage occurred. The efficacy of staple line reinforcement in the literature was unclear; however, reinforcement may be necessary for Zenker’s diverticulum cases.
- 13 February 2021
- Published by Wiley
Open AccessStaple line reinforcement to reduce leakage in open surgery for Zenker's diverticulum? A case report and literature review
A linear stapler was used to reduce the leakage rate during a Zenker’s diverticulum diverticulectomy. However, staple line reinforcement was not used, and leakage occurred. The efficacy of staple line reinforcement in the literature was unclear; however, reinforcement may be necessary for Zenker’s diverticulum cases.
- Open Access
- 22 July 2020
- Published by Springer Nature in BMC Surgery
- Vol. 20 (1) , 1-5
Systemic steroid application for treatment of edematous anastomotic stenosis following delta-shaped anastomosis in laparoscopic distal gastrectomy: a case report
Background: Delta-shaped anastomosis is a common method of intracorporeal gastroduodenostomy in totally laparoscopic distal gastrectomy. One common postoperative complication of this procedure is anastomotic stenosis, and endoscopic balloon dilatation is a major remedy for such complications. Other treatment strategies are necessary to manage unsuccessful endoscopic balloon dilatation. Case presentation: We present a case where systemic steroid treatment was applied in sustained anastomotic stenosis after endoscopic balloon dilatation. We performed delta-shaped anastomosis in laparoscopic distal gastrectomy to treat early-stage gastric cancer in a patient. The patient experienced abdominal pain post-surgery; subsequent investigation revealed edematous anastomotic stenosis. The stenosis sustained even after endoscopic balloon dilatation and local steroid injection. Consequently, we applied systemic steroid treatment. Conclusion: Systemic steroid treatment improved the stenosis and no recurrence was observed. These results suggest that systemic steroid application could be useful to treat anastomotic stenosis.
- 22 July 2020
- Published by Springer Nature in BMC Surgery
- Vol. 20 (1) , 1-5
Open AccessSystemic steroid application for treatment of edematous anastomotic stenosis following delta-shaped anastomosis in laparoscopic distal gastrectomy: a case report
Background: Delta-shaped anastomosis is a common method of intracorporeal gastroduodenostomy in totally laparoscopic distal gastrectomy. One common postoperative complication of this procedure is anastomotic stenosis, and endoscopic balloon dilatation is a major remedy for such complications. Other treatment strategies are necessary to manage unsuccessful endoscopic balloon dilatation. Case presentation: We present a case where systemic steroid treatment was applied in sustained anastomotic stenosis after endoscopic balloon dilatation. We performed delta-shaped anastomosis in laparoscopic distal gastrectomy to treat early-stage gastric cancer in a patient. The patient experienced abdominal pain post-surgery; subsequent investigation revealed edematous anastomotic stenosis. The stenosis sustained even after endoscopic balloon dilatation and local steroid injection. Consequently, we applied systemic steroid treatment. Conclusion: Systemic steroid treatment improved the stenosis and no recurrence was observed. These results suggest that systemic steroid application could be useful to treat anastomotic stenosis.